Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

dc.contributor.author	Torre Aláez, M.
dc.contributor.author	Matilla, A.
dc.contributor.author	Varela Calvo, María
dc.date.accessioned	2023-05-18T08:21:13Z
dc.date.available	2023-05-18T08:21:13Z
dc.date.issued	2022
dc.identifier.citation	Journal For Immunotherapy of Cancer, 10(11), (2022); doi:10.1136/jitc-2022-005457
dc.identifier.issn	2051-1426
dc.identifier.uri	http://hdl.handle.net/10651/68060
dc.description.statementofresponsibility	De La Torre-Aláez M., Matilla A., Varela M., Iñarrairaegui M., Reig M., Lledó J.L., Arenas J.I., Lorente S., Testillano M., Márquez L., Da Fonseca L., Argemí J., Gómez-Martin C., Rodriguez-Fraile M., Bilbao J.I., Sangro B.
dc.language.iso	eng
dc.relation.ispartof	Journal For Immunotherapy of Cancer
dc.rights	© Author(s) (or their employer(s)) 2022.
dc.rights	CC Reconocimiento - No Comercial 4.0 Internacional
dc.rights.uri	http://creativecommons.org/licenses/by-nc/4.0/
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143113580&doi=10.1136%2fjitc-2022-005457&partnerID=40&md5=64ce91ba280ee2a1b58205f62a22b970
dc.title	Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
dc.type	journal article
dc.identifier.doi	10.1136/jitc-2022-005457
dc.relation.publisherversion	http://dx.doi.org/10.1136/jitc-2022-005457
dc.rights.accessRights	open access
dc.type.hasVersion	VoR

Este ítem está sujeto a una licencia Creative Commons